Key facts
- Lvis’s last known valuation is $598.0M (Sep 2025).
- It has raised $73.8M; the latest was Later Stage VC ($20.0M) in Sep 2025.
- Notable investors include StartX (US), KB Investment, InterVest, A&E Investments, APL Ventures — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Lvis
- ·The full record, as it builds
Funding rounds
No funding rounds for Lvis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lvis
Developer of a brain network analysis tool designed to decode brain networks and find cures for neurological diseases. The company's tools provide live visualization for learning how the neurological disorder is diagnosed and treated, enabling physicians to understand the cause of neurological disorders and come up with treatments.
- Sector
- Healthcare
- HQ
- Palo Alto, CA, United States
- Founded
- 2013
- Employees
- 41
- Website
- lviscorp.com/
- Ownership
- Privately Held (backing)
Lvis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lvis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lvis in its N-PORT filings yet. We sweep new filings monthly.